1. Denmark Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharma Equity Group A/S Class A

Pharma Equity Group A/S Class A

CCPH:PEG
0.08
DKK
+0.00
(-1.00%)
149.76MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-93.59
-0.1
-0.13
-0.06
0.01
-0.32
-0.71
-1.03
0.1
-0.25
-0.02
-0.04
-0.02
- -
Free Cash Flow per Basic Share
-4.07
-0.08
-0.14
-0.01
-0.22
-0.07
-0.11
-0.31
-0.04
-0.08
-0.02
-0.02
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-69.58
4.49
4.37
4.34
3.5
3.26
2.11
1.08
1.14
1.23
0.02
0.03
0.02
0.03
Tangible Book Value per Share
-69.58
4.49
4.37
4.34
3.5
3.26
2.11
1.08
1.14
1.23
0.01
0.03
0.02
0.03
Basic Weighted Avg Shares
2
58
22
19
22
24
20
32
56
37
1,080
1,068
1,228
1,125
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-142
-6
-3
-1
- -
-8
-14
-33
5
-9
-24
-41
-25
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-162
-3
-7
97
85
76
74
-23
-14
46
33
41
29
54
LT Debt
150
- -
17
- -
- -
- -
- -
- -
7
- -
8
8
5
15
Total Equity
-105
98
100
97
85
78
67
34
43
46
25
33
25
39
Return on Invested Capital (%)
- -
- -
- -
- -
-2.1
- -
- -
- -
-2.73
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
2.13
- -
- -
- -
11.45
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-2.88
-1.1
0.2
-9.62
-19.92
-64.82
14.03
-21.32
-68.22
-139.99
-87.28
- -

Capital Structure

DKK

•

in mil. unless spec.
Sep'24
Dec'24
Jun'25
ST Debt
32
3
3
LT Borrowings
20
8
15
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,023
1,228
1,228
Market Capitalization
238
233
150

Working Capital

DKK

•

in mil. unless spec.
Sep'24
Dec'24
Jun'25
Total Current Assets
65
49
62
Cash, Cash Equivalents & STI
4
4
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
41
9
8
Payables & Accruals
- -
- -
- -
ST Debt
32
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.17%
-1.14%
-22.07%
Free Cash Flow
328.42%
90.76%
-22.75%
Net Income, GAAP
-462.69%
-40.89%
-37.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christian Henrik Tange
Full Time Employees
5
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Slotsmarken 18, 2.th. Hørsholm CR Denmark 2970
IPO Date
Jun 25, 2003
Website
pharmaequitygroup.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharma Equity Group A/S (PEG.CO) is a Danish investment company focused on the development and commercialization of pharmaceutical and biotech assets. The company acquires, finances, and advances late-stage clinical products targeting unmet medical needs in areas such as oncology, neurology, and rare diseases; it provides strategic funding, regulatory support, and partnership opportunities to portfolio companies. Its core offerings include equity investments in innovative drug candidates, milestone-based financing models, and operational expertise for clinical trial execution and market entry. Headquartered in Copenhagen, Denmark, and founded in 2016, Pharma Equity Group operates primarily in Europe with expanding interests in North American markets. Recent developments include a strategic alliance with a leading Nordic biotech firm in Q4 2025 to co-develop an oncology pipeline asset, alongside a NOK 150 million funding round closed in September 2025 to support Phase III trials for its flagship neurology program.